Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
[3H]ketanserin attaches to 5-HT2 receptors in the frontal cortex of human and bovine brains in the presence of loxapine, with Ki values of 6.2 nM and 6.6 nM, respectively. The potency of loxapine at different receptors was graded as follows in competition assays employing human membranes: 5-HT2≥D4>>>>>D1>D2[1]. In LPS-activated mixed glial cell cultures, loxapine (0–20 μM) decreases IL-1β secretion; in mixed glial cell cultures, it decreases IL-2 secretion; and in microglia cells, it decreases LPS-induced IL-1β and IL-2 secretion [2].
|
---|---|
ln Vivo |
In the rat brain, loxapine (5 mg/kg; i.p.; daily for 4 or 10 weeks) reduces serotonin (S2) but does not raise the number of dopamine (D2) receptors [3].
|
Animal Protocol |
Animal/Disease Models: Adult male Wistar rat (150-175 g) [3]
Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection, one time/day for 4 or 10 weeks Experimental Results: Induced significant reduction in serotonin (S2) (more than 50%)) daily injections increased receptor density after 4 or 10 weeks, but did not produce any significant increase in dopamine receptor density. |
References |
[1]. Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35.
[2]. Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30. [3]. Lee T, et al. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85. [4]. Kalkman HO, et al. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):361-4. [5]. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013 Jun;27(6):479-89. [6]. Yang CY, et al. Loxapine, an antipsychotic drug, suppresses intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages. J Microbiol Immunol Infect. 2019 Aug;52(4):638-647. |
Molecular Formula |
C18H18CLN3O
|
---|---|
Molecular Weight |
327.812
|
Exact Mass |
327.1138
|
CAS # |
1977-10-2
|
Related CAS # |
Loxapine succinate;27833-64-3;Loxapine hydrochloride;54810-23-0;Loxapine-d8 hydrochloride;1246820-19-8;Loxapine-d8;1189455-63-7
|
SMILES |
CN1CCN(C2=NC3=CC=CC=C3OC4=CC=C(Cl)C=C24)CC1
|
Synonyms |
CL 62,362; AZ-004; Adasuve
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 33.33 mg/mL (~101.67 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0505 mL | 15.2527 mL | 30.5055 mL | |
5 mM | 0.6101 mL | 3.0505 mL | 6.1011 mL | |
10 mM | 0.3051 mL | 1.5253 mL | 3.0505 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.